How to Get Dayvigo (Lemborexant) in Missouri

What Is Dayvigo and Why Missouri Patients Seek It

Dayvigo is the brand name for lemborexant, a dual orexin receptor antagonist (DORA) that blocks the wake-promoting OX1R and OX2R receptors in the brain rather than broadly suppressing the central nervous system the way benzodiazepines do. The FDA approved it on December 20, 2019, for adults with chronic insomnia disorder at doses of 5 mg and 10 mg taken no more than once per night immediately before bed, with at least 7 hours remaining before the planned wake time. 1

The key SUNRISE-1 trial (N=1,006, 12-month duration) published in JAMA Network Open showed that lemborexant 5 mg and 10 mg both significantly improved subjective sleep onset latency and sleep efficiency versus placebo at month 1 (P<0.001 for both doses), with the 10 mg arm also outperforming zolpidem extended-release 6.25 mg on polysomnographic sleep onset latency at months 1 and 6. 2 Missouri patients with chronic insomnia who have tried or cannot tolerate benzodiazepines, non-benzodiazepine hypnotics (Z-drugs), or melatonin receptor agonists are often specifically asking for Dayvigo because its mechanism produces less morning sedation than older agents at therapeutic doses.

The American Academy of Sleep Medicine 2017 clinical practice guidelines recommend pharmacotherapy as an adjunct to cognitive behavioral therapy for insomnia (CBT-I) when CBT-I alone is insufficient. 3 Lemborexant fits that adjunct role for patients where orexin blockade is clinically preferred over GABA-A modulation.

Missouri Telehealth Rules for Controlled-Substance Prescribing

Missouri permits telehealth prescribing of Schedule IV controlled substances, including lemborexant, after a synchronous real-time audio-video encounter that satisfies the state's prescriber-patient relationship requirements. Missouri's telehealth statute (RSMo §191.1145) does not require an in-person visit before a telehealth prescription may be issued, provided the prescriber can conduct a sufficient clinical evaluation via video. 4

The federal Ryan Haight Act ordinarily requires an in-person exam before a practitioner may prescribe a Schedule III-V controlled substance via the internet. The DEA's COVID-era telemedicine flexibilities extended through December 31, 2025, currently allow Schedule IV prescriptions via audio-video telehealth without a prior in-person visit for registered practitioners. 5 Missouri-licensed physicians, nurse practitioners, and physician assistants with DEA registration may therefore prescribe lemborexant to Missouri patients via telehealth video visit today, subject to DEA extension status at the time of the appointment.

Telehealth platforms serving Missouri typically complete intake paperwork, a structured sleep questionnaire (such as the Insomnia Severity Index), and the synchronous video visit within a single session averaging 20 to 30 minutes. Prescriptions are transmitted electronically to a Missouri pharmacy or a mail-order pharmacy licensed in Missouri.

Who Can Prescribe Dayvigo in Missouri

Missouri law grants prescribing authority for Schedule IV substances to licensed physicians (MD/DO), nurse practitioners with a collaborative practice arrangement or independent practice authority, and physician assistants under physician supervision. 6

Missouri NPs who have completed the 6,000-hour collaborative practice requirement may practice independently and hold their own DEA registration, which allows them to prescribe lemborexant without co-signature from a supervising physician. PAs in Missouri still require a supervising physician's oversight, but the supervising physician does not need to co-sign each controlled-substance prescription in real time. Sleep medicine specialists, psychiatrists, primary care physicians, and internists all routinely prescribe Dayvigo. There is no regulatory requirement that insomnia pharmacotherapy be initiated only by a sleep specialist.

The American College of Physicians guideline statement reads: "ACP recommends that clinicians use pharmacological therapy as a second-line treatment for adult patients with chronic insomnia disorder after CBT-I has been tried." 7 Any licensed Missouri prescriber with DEA authority may fulfill that second-line role.

Step-by-Step: Getting a Dayvigo Prescription in Missouri

Getting Dayvigo in Missouri follows a predictable five-step path regardless of whether you use an in-person or telehealth provider.

Step 1. Document your insomnia history. Compile at least two weeks of sleep diary data (bedtime, wake time, total sleep time, number of awakenings) before the appointment. Insurers and prescribers both expect documentation that the insomnia is chronic, meaning it occurs at least three nights per week for at least three months per DSM-5 criteria. 8

Step 2. Schedule a clinical visit. Book an in-person appointment or a telehealth video visit with a Missouri-licensed provider. Many telehealth platforms offer same-week availability. The visit will include a structured sleep history, review of medications that may cause or worsen insomnia, screening for obstructive sleep apnea (OSA) using the STOP-BANG or Epworth Sleepiness Scale, and assessment of comorbid mood disorders.

Step 3. Discuss prior treatments tried. Most Missouri commercial insurers require evidence that the patient has tried at least one or two generic hypnotics before approving Dayvigo. Documenting a trial of generic zolpidem, eszopiclone, or doxepin strengthens the prior authorization case. If CBT-I was attempted and failed or was inaccessible, document that too.

Step 4. Receive the prescription and begin prior authorization if applicable. The prescriber sends the e-prescription to your chosen pharmacy. If insurance requires prior authorization, the prescriber's office submits the PA request. PA turnaround for Missouri commercial plans typically runs 3 to 7 business days.

Step 5. Fill at a Missouri pharmacy or mail-order. Licensed retail pharmacies statewide stock or can order Dayvigo. Mail-order pharmacies licensed in Missouri can ship directly to your address, typically within 2 to 5 business days after the prescription is verified.

Labs and Clinical Screening Before Dayvigo

No mandatory laboratory tests are required by the FDA label before initiating lemborexant. 1 The prescriber will, however, conduct clinical screening that may include liver function tests if hepatic impairment is suspected, because the Dayvigo prescribing information contraindicates use in patients with severe hepatic impairment and recommends the 5 mg maximum dose in moderate hepatic impairment.

Screening for OSA matters clinically: DORAs including lemborexant mildly suppress respiratory drive at therapeutic doses, and a 2020 pharmacodynamic study found lemborexant 10 mg produced no clinically significant worsening of apnea-hypopnea index in mild-to-moderate OSA patients, though the FDA label still advises caution in patients with compromised respiratory function. 9

A urine drug screen is not required by the label but may be ordered at the prescriber's discretion, particularly in patients with a known history of substance use disorder. Lemborexant carries a lower abuse potential than benzodiazepines based on Phase 1 abuse-potential studies submitted to the FDA, which contributed to its Schedule IV (rather than Schedule III) placement. 10

The following clinical triage framework is used by HealthRX-affiliated providers when evaluating Missouri patients for lemborexant candidacy:

1. Confirm chronic insomnia disorder (DSM-5: 3 nights/week for 3+ months, causing daytime impairment).
2. Exclude secondary insomnia causes: thyroid dysfunction, depression, OSA, medications (stimulants, steroids, beta-blockers).
3. Document CBT-I access attempt or active referral.
4. Review prior hypnotic trials (Z-drugs, doxepin, melatonin, trazodone) and reasons for discontinuation.
5. Screen for severe hepatic impairment (Child-Pugh C) or narcolepsy, both absolute contraindications per FDA label.
6. Assess fall risk, especially in patients over age 65, given next-day somnolence data from SUNRISE-2.
7. Select starting dose: 5 mg in elderly patients, those on moderate CYP3A inhibitors, or patients with moderate hepatic impairment. 10 mg for otherwise healthy adults if rapid efficacy is needed.

Insurance Coverage and Prior Authorization in Missouri

Missouri Medicaid (MO HealthNet) does not cover Dayvigo for insomnia. The formulary restricts coverage of Schedule IV sleep aids to patients with type 2 diabetes in specific circumstances; lemborexant is not on the MO HealthNet preferred drug list for insomnia as of 2025. 11

Commercial insurance coverage varies by plan. Medicare Part D covers lemborexant on several plan formularies, typically on Tier 3 or Tier 4, with copays ranging from $45 to $110 per month depending on the plan. The Eisai patient assistance program (Dayvigo Together) provides the medication at no cost to eligible patients with household income below 400% of the federal poverty level and no insurance coverage for the drug. 12

Prior authorization for commercial plans in Missouri commonly requires documentation of:

• Diagnosis of chronic insomnia disorder (ICD-10 G47.00).
• Failure of at least one generic hypnotic at an adequate dose and duration (typically 2 to 4 weeks).
• Absence of a clinical reason to prefer generic alternatives.
• Attestation that CBT-I was offered or attempted.

The Annals of Internal Medicine noted that PA requirements for insomnia medications create a meaningful access barrier, particularly for patients with comorbid psychiatric conditions who have higher rates of PA denial on first submission. 7 Patients should ask their prescriber to submit the PA with full clinical documentation on the first attempt to avoid delays.

503A Compounding of Lemborexant in Missouri

Missouri-licensed 503A compounding pharmacies may prepare patient-specific formulations of lemborexant for patients who cannot use the commercially manufactured tablet. FDA regulations allow 503A pharmacies to compound FDA-approved drug substances into alternative dosage forms for individual patients when there is a valid prescriber-patient relationship and a legitimate medical need, such as dysphagia requiring a liquid formulation. 13

503A pharmacies cannot compound lemborexant to sell to prescribers for office stock or to circumvent the commercial product. The compound must differ from the FDA-approved tablet in a clinically meaningful way (different dose strength not commercially available, different dosage form). Missouri Board of Pharmacy licensure is required for any pharmacy compounding within the state. 14

Cost may be lower through a 503A pharmacy if the compounded formulation is not subject to brand pricing, but patients should confirm the compounding pharmacy's PCAB accreditation and sourcing of USP-grade lemborexant API.

How Long Until You Receive Dayvigo in Missouri

From first telehealth appointment to dispensing, most Missouri patients receive Dayvigo within 3 to 10 business days. The breakdown by step looks like this:

• Telehealth visit to prescription transmission: same day (typically within 2 hours of appointment end).
• Retail pharmacy order and dispense (if not stocked): 1 to 3 business days.
• Prior authorization, if triggered: 3 to 7 business days (expedited PA for acute situations: 24 to 72 hours).
• Mail-order pharmacy shipping: 2 to 5 business days after prescription verification.

Patients who choose a retail pharmacy that stocks Dayvigo and who do not require prior authorization (for example, cash-pay patients using a GoodRx or manufacturer coupon) can fill the prescription the same day as the telehealth visit. Cash price with the Eisai savings card brings the out-of-pocket cost below $30 per month for commercially insured patients who meet eligibility criteria.

Transferring a Dayvigo Prescription to Missouri

A Dayvigo prescription issued in another state can be transferred to a Missouri pharmacy with some restrictions. Schedule IV controlled substance prescriptions may be transferred between pharmacies one time only under federal DEA regulations. 15 The receiving Missouri pharmacy must be DEA-registered, and the transferring pharmacy must cancel the original prescription upon transfer.

If you have received multiple refills on an out-of-state prescription, only the remaining refills can be transferred. Missouri pharmacies can dispense controlled substance prescriptions written by out-of-state licensed practitioners as long as the prescription is valid under both the issuing state's law and Missouri law. If your out-of-state prescriber is not licensed in Missouri, you will need a new prescription from a Missouri-licensed provider before a Missouri pharmacy can fill it.

Telehealth platforms licensed in Missouri can often see you within days and issue a new prescription to a Missouri pharmacy, making the prescriber-licensure issue straightforward for most patients.

Dayvigo Safety, Side Effects, and Next-Day Driving

SUNRISE-2 (N=949, 12-month maintenance trial) showed that somnolence and fatigue were the most common treatment-emergent adverse events with lemborexant 10 mg, occurring in 10.4% of patients versus 2.9% on placebo. 16 The 5 mg dose produced somnolence in 6.9% of patients. Sleep paralysis and hypnagogic hallucinations were reported in less than 2% of participants in both SUNRISE trials.

The FDA label warns that next-day driving impairment is possible even at the 5 mg dose in some patients. Missouri patients should not drive or operate heavy machinery the morning after taking lemborexant until they know how the drug affects their individual alertness. 1 Patients over age 65 showed a modestly higher rate of somnolence and fall events in post-marketing surveillance, supporting the label recommendation to start with 5 mg in older adults.

CYP3A4 interaction matters: strong CYP3A inhibitors (clarithromycin, itraconazole, ritonavir) can raise lemborexant plasma concentrations significantly. The prescribing information recommends against concurrent use of lemborexant with strong CYP3A inhibitors. Moderate inhibitors (fluconazole, erythromycin, diltiazem) warrant dose reduction to 5 mg maximum. 1

Lemborexant is contraindicated in patients with narcolepsy. The drug's mechanism of blocking orexin signaling would worsen cataplexy and sleep attacks in narcoleptic patients.

Dayvigo vs. Other Insomnia Medications Available in Missouri

Missouri prescribers have access to the full range of FDA-approved insomnia therapies. Here is how lemborexant compares to the most commonly prescribed alternatives:

Zolpidem (Ambien, generic): Widely available, low cost. Acts on GABA-A receptors. Associated with complex sleep behaviors (sleepwalking, sleep-driving), residual sedation, and tolerance with extended use. The FDA lowered recommended doses for women to 5 mg IR in 2013 due to morning impairment data. 17

Eszopiclone (Lunesta, generic): Schedule IV, no official duration-of-use limit per FDA label. Metallic taste side effect in approximately 34% of patients. Effective for sleep maintenance insomnia. Generic cost is low.

Suvorexant (Belsomra): The first FDA-approved DORA, approved 2014. Mechanism class is the same as lemborexant. Head-to-head data from SUNRISE-1 showed lemborexant 10 mg outperformed zolpidem ER but no direct head-to-head trial versus suvorexant has been published in a peer-reviewed journal. 2

Doxepin 3 mg / 6 mg (Silenor): Histamine H1 antagonist, approved specifically for sleep maintenance insomnia. Non-scheduled. Lower abuse potential. Often the first non-benzodiazepine non-Z-drug option trialed when insurers require step therapy.

Melatonin receptor agonist ramelteon (Rozerem): Non-scheduled. Effective for sleep onset, less so for maintenance. Useful in patients with substance use disorder history where Schedule IV agents are not preferred.

Lemborexant 10 mg holds a meaningful advantage in polysomnographic sleep onset latency versus zolpidem ER based on SUNRISE-1 data 2, and its mechanism avoids the complex sleep behavior risk associated with Z-drugs. These characteristics make it a preferred choice when the prescriber and patient prioritize next-day function and safety over cost.